anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
miR-196a has important roles in the pathoetiology of different disorders ranging from non-malignant to malignant ones. This miRNA is transcribed from two genomic loci, namely HOXC and HOXB on human chromosomes 12 and 17, respectively. The current study aims to summarize the role of miR-196a in different disorders. In the most conducted studies in the framework of cancer, miR-196a has been identified as an oncogene. However, few studies are not conformed to this concept. In head and neck, lung, oral and pancreatic cancers, miR-196a is a possible diagnostic marker. In addition, it has a possible role in the pathoetiology of diabetic nephropathy, Huntington's disease, idiopathic male infertility, keloid, chronic kidney disease and spinal and bulbar muscular atrophy; and is regarded as a biomarker for focal segmental glomerulosclerosis and chronic kidney disease. We aim to recapitulate the role of miR-196a in different malignant and non-malignant disorders.
This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
PURPOSE:To obtain a skin-beautifying cosmetic having high safety to skin and effective in suppressing the formation of melanin pigment and in rapidly bleaching dark skin, by using calcium hopantenate in combination with L- ascorbic acids. CONSTITUTION:The objective cosmetic contains (A) calcium hopantenate and (B) one or more compounds selected from L-ascorbic acid, its derivative and their salt, e.g. ascorbic acid esters such as 3-O-ethyl 6-acyl-L-ascorbate as essential components. The amount of the component A is 0.05-2.0wt.%, preferably 0.1-1.5wt.% and that of the component B is 0.5-10.0wt.% based on the whole cosmetic. The above effect can be exhibited by the synergistic effect of the component B to suppress the formation of melanin pigment and to reductively decolor the pigment and of the component A to promote the metabolism of pigment cell by the blood flow promotion and skin function promotion effect. The skin-beautifying cosmetic can be applied even to a sunburnt skin without irritation.
Participants randomized to this group will receive a 12-month automated weight loss program which is delivered via the Internet and will also receive a 9-month Iyengar yoga intervention (delivered during months 4-12). Yoga classes will be delivered live (via Zoom) and participants will be instructed to attend two classes per week for the first 14 weeks and one class per week thereafter. They will also be asked to do self-guided yoga practice on their own and report their yoga practice on the study website.
If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
Systems and methods for providing an electronic medical record, recommendation, or alert associated with a patient to a healthcare provider based on an analysis of the patient's health data. The plurality of electronic repositories may store patient health data as resolved health data. The patient's health data may be organized in a healthcare identity graph to provide a comprehensive medical history of the user. The patient's device may access and analyze the patient's health data in response to detecting the event. The device may generate an output or trigger action based on an analysis of the patient's health data and record the output or action in a healthcare identity map of the patient. The authentication and verification of the output or action is stored in the healthcare responsibility diagrams.
Gadobutrol injection Imaging Bulk Package (IBP) is a container of a sterile preparation for parenteral use that contains many single doses of gadobutrol for use with a medical imaging device. Gadobutrol injection Imaging Bulk Package is for intravenous use and not for direct infusion. Gadobutrol injection Imaging Bulk Package is for use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. Please see drug and device labeling for information on devices indicated for use with this Imaging Bulk Package and techniques to help assure safe use. 

  1. The Gadobutrol injection Imaging Bulk Package is to be used only in a room designated for radiological procedures that involve intravascular administration of a contrast agent. 
  2. Utilize aseptic technique for penetrating the container closure of the Gadobutrol injection Imaging Bulk Package and transferring Gadobutrol injection. 
  3. The container closure must be penetrated only one time with a suitable sterile component of the automated contrast injection system, contrast management system, or contrast media transfer set (e.g., transfer spike) approved or cleared for use with this contrast agent in this Imaging Bulk Package. 
  4. Once the Gadobutrol injection Imaging Bulk Package is punctured, do not remove it from the work area during the entire period of use. Storage temperature of Gadobutrol injection Imaging Bulk Package after the closure has been entered is 20°C to 25°C (68°F to 77°F). 
  5. A maximum use time of 24 hours from initial puncture is permitted to complete fluid transfer. Discard any unused Gadobutrol injection 24 hours after initial puncture of the Imaging Bulk Package. 
  6. After the container closure is punctured, if the integrity of the Imaging Bulk Package and the delivery system cannot be assured through direct continuous supervision, the Imaging Bulk Package and all associated disposables for the automated contrast injection system, contrast management system, or contrast media transfer set (e.g., transfer spike) should be discarded.
Invention herewith described refers to the therapy with cross-linked immunoglobulins - atherosclerosis in different indications, immunological tolerance and protective immunity i.e. to the use of immunoglobulin (Ig) reactive with other immobilized Ig-molecules in the passive therapy in indications such as atherosclerosis, various inflammatory diseases, weakened immune tolerance and protective immunity, here identified as cross-linked Ig (ConIg). The invention relates to Conlg containing IgG (97%) and the traces of IgM and IgA, here identified as ConlgG. In other case the Conlg depending on the procedure can contain different percentage of IgG, IgM and IgA isotopes, in the range of 22% - 67% i.e. 12% - 28% i.e. 20% - 51%, here identified as ConlgGMA. However, all preparations show a higher IgG2/IgGl ratio of the antibodies contrary to the normal human serum (NHS) and the commercial intravenous Ig-s (IVIG). The IgM antibodies present in ConlgGMA efficiently bind oxidatively modified low density lipoproteins (oxLDL), and this binding is partially inhibited with phosphorylcholine (PC)-BSA conjugate, one common hapten for oxLDL and the apoptotic cells (AC), which indicates its atheroprotective feature. Therefore Conlg-or can also have positive effect in autoimmune diseases with frequent atherosclerosis and coronary artery diseases (CAD), such as antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and in HIV-infected patients after antiretroviral therapy.
Impaired episodic future thinking (EFT), as reflected in reduced specificity, low levels of detail and less use of mental imagery, has been associated with depressive symptomatology. The beneficial impact of Future Event Specificity Training (FEST) on impaired EFT has recently been demonstrated, as well as on anhedonia, the core symptom of depression reflecting low positive affect. The current study aimed to replicate these previous findings. In addition, this study is the first to examine the potential of FEST to reduce engagement in dampening, a maladaptive response style characterised by reducing the intensity and/or frequency of positive emotional states, which is linked to depressive symptoms and anhedonia. An RCT (FEST vs. waitlist control) was conducted in a large sample of Dutch-speaking undergraduate students (N = 155). In line with prior research, FEST resulted in significant improvements in EFT features. However, likely related to limited room for change detection, no significant changes were found in anhedonia and dampening. In the light of the positive impact of FEST on several EFT features, future studies should address methodological issues to create optimal conditions for potential change detection. Finally, further examination of the proposed theoretical change mechanisms aimed to reduce anhedonia and dampening is warranted.
The researchers met the pregnant women in antenatal clinics during their routine follow up. Woman who was eligible to be recruited in the study signed the consent after description of the study's purpose. Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. Further, each pregnant woman in the study group was trained how to count the fetal movement (i.e.lying down on her left side after taking her meal, and concentrating on fetal movements, calculate it three times per day, half an hour/ one time and record it in the chart). As a rule, if there are less than 10 movements felt in 2 hours, women should contact her health care provider immediately (Royal college of obstetrician \& gynecologists, 2011). Fetal movements counting chart was provided and women telephoned once a week in order to ensure proper recording. They also asked to present the fetal movements' chart to the researcher and thier health care providers in each antenatal follow up visit. Pregnant women in both groups; the study and the control groups followed according to thier antenatal visits schedule till delivery. Women in the control group received the antenatal hospital standard care. The maternal and neonatal outcomes had been assessed at delivery unit.
Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Prolonged vasospasm was defined for patients who persisted with vasospasm after day 21 of cerebral bleeding.
A hydraulic cement comprising a calcium silicate and at least one phosphate compound. The phosphate compound is included in an amount sufficient to react a major portion of the calcium hydroxide that is produced during hydration of the cement to hydroxyapatite or other calcium phosphates. The phosphate compound is preferably a mono-calcium phosphate. The cement is useful in both bio-medical/dental and engineering applications. The calcium hydroxide is reacted by the phosphate to form hydroxiapatite or other calcium phosphate that is co-precipitated with the calcium silicate hydrate to form a composite-like structure on a nano-scale level. The reduced calcium hydroxide content in the set cement increases its strength and reduces its pH. The hydroxiapatite content and the reduced pH render the cement bio-active and suitable for use in medical and dental implants, for example, for replacement bone and tooth material. Due to its high strength, the cement may also be used for structural/engineering applications.
No intervention for initial 6 months (wait list), then BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing 6 months after enrollment. Optional on the part of subject.
The current gold standard for the treatment of proliferative diabetic retinopathy is panretinal photocoagulation. Therefore this study is designed using both treatments in the same patient: intravitreal Bevacizumab plus panretinal photocoagulation in one eye, compared to panretinal photocoagulation alone in the contralateral eye. These patients had their visual acuity and contrast vision measured and complete ophthalmological examination was performed, including macular slit lamp examination, fluorescein angiography and optical coherence tomography.

Patients with similar proliferative diabetic retinopathy without high risk characteristics receive laser therapy in both eyes and intravitreal Bevacizumab injections in one eye. For the Bevacizumab injections, numbing drops, antibiotic drops, and drops to dilate the pupil, and possibly and anesthetic injection, are put in the eye before the medicine is injected into the vitreous. Patients return for follow-up visits 1 day, 1 and 4 weeks after the injection, and then 3 and 6 months. Patients whose condition does not improve may undergo new evaluation.
The present invention relates to mesoporous organosilica nanoparticles formed by elements comprising or consisting of (i) a porphyrin derivative such as, for example, a compound of formula A (ii) a compound of formula (EtO)3Si(CH2)nSi(OEt)3, in which n represents an integer selected from 1 to 10, and optionally (iii) a compound of formula (EtO)3Si(CH 2)3-(SS)m-(CH2)3-Si(OEt)3 wherein m is an integer equal to 2 or 4, said nanoparticles optionally encapsulating at least one hydrophilic and/or hydrophobic anticancer compound. A use of nanoparticles as a photosensitizer. A pharmaceutical composition comprising the nanoparticles and a pharmaceutically acceptable vehicle. A process for manufacturing nanoparticles. Mesoporous nanoparticles obtained through the above-mentioned process. A kit for detecting a pathology comprising the nanoparticles or a drug composition comprising them and means allowing LED irradiation, blue to near-infrared laser.
PURPOSE:The titled composition, consisting essentially of polyvinyl alcohol, consisting of completely saponified polyvinyl alcohol and partially saponified polyvinyl alcohol together and having improved tackiness to the skin and water. CONSTITUTION:An adhesive gel composition, consisting essentially of polyvinyl alcohol (PVA) and water and containing (A) 7-30wt% completely saponified PVA with >=95mol% saponification degree and >=500 average polymerization degree and (B) 5-30wt% partially saponified PVA with >=85mol% saponification degree and >=200 average polymerization degree and useful as a base of an anti-inflammatory hydrous application agents, e.g. anti-inflammatory and analgesic agents, cooling tools, etc. The above-mentioned composition has tough skeleton of gel and improved shape retaining property and water holding property. Since the tackiness thereof is excellent, handling is readily carried out without requiring the use of adhesive tapes, etc. Thereby the composition can be widely applied to local cold insulants, cataplasm plaster, gel for bioelectrodes, etc.
The initial dosage of prednisone tablets may vary from 5 mg to 60 mg per day, depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
An animal feed supplement for use in an animal food composition containing an animal feed having monocalcium phosphate therein is disclosed. The supplement comprises monensin, a solvent, and an alkaline component. The supplement is a mixture, and the alkaline component is present in the animal feed supplement in an amount sufficient to maintain the ability to detect monensin in the animal food composition. An animal food composition, comprising the above described animal feed supplement is disclosed. The animal feed also has monocalcium phosphate therein. The above described animal food composition is useful for preventing or treating coccidiosis in an animal for example a bovine.
The subjects included in the course content were given between 10:00-12:00 with the animation supported method, which lasted for 2 hours. The animations were created by the researchers to reflect all guidelines for diabetes. The scenario of the animation video was prepared in line with the training content. Storyboards in videos and animations were created with the collaboration of researchers and experts in their fields (software specialists, computer programmers). The animation video was voiced in Turkish by a professional actor. Animations are 2 minutes each and a total of 18 minutes long. The 'Kahoot' application, a Web 2.0 tool, was used to apply Diabetes Achievement Evaluation Test. At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels.
PURPOSE: An E. coli strain is provided to show synergistic effect of two kinds of active ingredients and to be used as an anticancer agent with low toxicity and superior immunogenicity. CONSTITUTION: An E. coli strain produces lipooligosaccharides with a molecular weight of 2,000-5,000 Da. The lipooligosaccharides contain a sugar chain of chemical formula 1. A chromosomal DNA of the E. coli strain generates oligodeoxynucleotide with immunostimulatory activity. The lipooligosaccharides contain lipids of 3-hydroxytetradecanoate trimethylsilyl ester. The E. coli strain is E. coli EG0023 (KCCM11218P).
BACKGROUND: Inflammation and immunity contribute pivotally to diverse acute and chronic diseases. Inflammatory pathways have become increasingly targets for therapy. Yet, despite substantial similarity in mechanisms and pathways, the scientific, medical, pharma and biotechnology sectors have generally focused programs finely on a single disease entity or organ system. This insularity may impede progress in innovation and the harnessing of powerful new insights into inflammation biology ripe for clinical translation.
METHODS: A multidisciplinary thinktank reviewed highlights how inflammation contributes to diverse diseases, disturbed homeostasis, ageing and impaired healthspan. We explored how common inflammatory and immune mechanisms that operate in key conditions in their respective domains. This consensus review highlights the high degree of commonality of inflammatory mechanisms in a diverse array of conditions that together contribute a major part of the global burden of morbidity and mortality and present an enormous challenge to public health and drain on resources.
RESULTS: We demonstrate how that shared inflammatory mechanisms unite many seemingly disparate diseases, both acute and chronic. The examples of infection, cardiovascular conditions, pulmonary diseases, rheumatological disorders, dementia, cancer and ageing illustrate the overlapping pathogenesis. We outline opportunities to synergize, reduce duplication and consolidate efforts of the clinical, research and pharmaceutical communities. Enhanced recognition of these commonalties should promote cross-fertilization and hasten progress in this rapidly moving domain.
CONCLUSIONS: Greater appreciation of the shared mechanisms should simplify understanding seemingly disparate diseases for clinicians and help them to recognize inflammation as a therapeutic target which the development of novel therapies is rendering actionable.
In elderly and debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation (10 mg or less per day initially, to be increased gradually as needed and tolerated). In general, the concomitant administration of chlordiazepoxide and other psychotropic agents is not recommended. If such combination therapy seems indicated, careful consideration should be given to the pharmacology of the agents to be employed - particularly when the known potentiating compounds such as MAO inhibitors and phenothiazines are to be used. The usual precautions in treating patients with impaired renal or hepatic function should be observed.

Paradoxical reactions, e.g., excitement, stimulation and acute rage, have been reported in psychiatric patients and in hyperactive aggressive pediatric patients, and should be watched for during chlordiazepoxide therapy. The usual precautions are indicated when chlordiazepoxide is used in the treatment of anxiety states where there is any evidence of impending depression; it should be borne in mind that suicidal tendencies may be present and protective measures may be necessary. Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects on blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide. In view of isolated reports associating chlordiazepoxide with exacerbation of porphyria, caution should be exercised in prescribing chlordiazepoxide to patients suffering from this disease.